isatuximab
E852349
CD38-targeting antibody
anticancer drug
biologic medicinal product
immunoglobulin G1
monoclonal antibody
protein-based drug
Isatuximab is a monoclonal antibody drug used primarily in the treatment of multiple myeloma by targeting and killing malignant plasma cells.
Statements (46)
| Predicate | Object |
|---|---|
| instanceOf |
CD38-targeting antibody
ⓘ
anticancer drug ⓘ biologic medicinal product ⓘ immunoglobulin G1 ⓘ monoclonal antibody ⓘ protein-based drug ⓘ |
| actsOnCellType |
CD38-expressing hematologic tumor cells
ⓘ
malignant plasma cells ⓘ |
| administrationSchedule | repeated intravenous infusions in 28-day cycles ⓘ |
| approvedBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| ATCCode | L01FX09 ⓘ |
| bindsTo | CD38 antigen on plasma cells ⓘ |
| commonAdverseEffect |
anemia
ⓘ
diarrhea ⓘ fatigue ⓘ infusion-related reaction ⓘ neutropenia ⓘ pneumonia ⓘ thrombocytopenia ⓘ upper respiratory tract infection ⓘ |
| developer | Sanofi NERFINISHED ⓘ |
| drugClass |
antineoplastic agent
ⓘ
immunomodulating agent ⓘ monoclonal antibodies against CD38 ⓘ |
| EMAAuthorizationYear | 2020 ⓘ |
| FDAApprovalYear | 2020 ⓘ |
| hasINN | isatuximab ⓘ |
| hasTradeName | Sarclisa NERFINISHED ⓘ |
| indication |
multiple myeloma
ⓘ
refractory multiple myeloma ⓘ relapsed multiple myeloma ⓘ |
| marketingAuthorizationHolder | Sanofi NERFINISHED ⓘ |
| mechanismOfAction |
induces antibody-dependent cellular cytotoxicity
ⓘ
induces antibody-dependent cellular phagocytosis ⓘ induces complement-dependent cytotoxicity ⓘ induces direct apoptosis of tumor cells ⓘ |
| molecularType | recombinant monoclonal antibody ⓘ |
| routeOfAdministration | intravenous infusion ⓘ |
| targetLocation | cell surface of plasma cells ⓘ |
| targets | CD38 NERFINISHED ⓘ |
| therapeuticArea |
hematologic malignancies
ⓘ
oncology ⓘ |
| usedWith |
carfilzomib
ⓘ
dexamethasone NERFINISHED ⓘ pomalidomide ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.